Table 1. The characteristics of 46 patients.
| Enrolled patients |
|
46 |
| Gender |
Male |
46 (100%) |
| Age (years) |
Median |
66 (range 54–83) |
| Stage (UICC2009) | T1c 17 | T1 17 (37%) |
| T2a 5, T2b 3, T2c 6 | T2 14 (30%) | |
| |
T3a 13, T3b 2 |
T3 15 (33%) |
| Initial PSA (ng ml−1) |
Median |
11.1 (range 3.559–242.7) |
| Gleason score | 3+3=6 | 12 (26%) |
| 3+4=7 | 6 (13%) | |
| 4+3=7 | 9 (20%) | |
| 4+4=8 | 8 (17%) | |
| |
4+5=9 |
11 (24%) |
| Risk | Low | 12 (26%) |
| Intermediate | 9 (20%) | |
| |
High |
25 (54%) |
| ADT | With ADT | 45 (98%) |
| Castration | (1) (2%) | |
| |
Without ADT |
1 (denied) (2%) |
| Median (range) duration of ADT by risk (months) | Low risk | 7.7 (5.5–25.2) |
| Intermediate risk | 10.0 (7.3–28.3) | |
| High risk | 26.7 (9.7–52.9)a |
Abbreviations: ADT=androgen deprivation therapy; PSA=prostate-specific antigen.
a
One patient who underwent castration was excluded (duration of ADT: 3.5 months).